Early Clinical Outcomes of the First Commercialized Human Autologous Ex Vivo Cultivated Oral Mucosal Epithelial Cell Transplantation for Limbal Stem Cell Deficiency: Two Case Reports and Literature Review

Early Clinical Outcomes of the First Commercialized Human Autologous Ex Vivo Cultivated Oral Mucosal Epithelial Cell Transplantation for Limbal Stem Cell Deficiency: Two Case Reports and Literature Review

The first product in the world for ex vivo cultivated oral mucosal epithelial cell transplantation (COMET) to treat limbal stem cell deficiency (LSCD), named Ocural<sup>®</sup>, was launched in June 2021 in Japan. COMET was performed on two patients, including the first case in the post-...

Full description

Bibliographic Details
Main Authors: Hiroshi Toshida, Tomoto Kasahara, Masamichi Kiriyama, Yuma Iwasaki, Jobu Sugita, Kohei Ichikawa, Toshihiko Ohta, Katsumi Miyahara
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:International Journal of Molecular Sciences
Subjects:
limbal stem cell deficiency
cultivated oral mucosal epithelial cell transplantation
stem cell
regeneration therapy
COMET
Ocural<sup>®</sup>
Online Access:https://www.mdpi.com/1422-0067/24/10/8926

Internet

https://www.mdpi.com/1422-0067/24/10/8926

Similar Items